Intrinsic tenase complex (Factor IXa-Factor VIIIa complex) (Intrinsic Xase)

The intrinsic tenase complex is a multi-protein enzyme assembly that plays a central role in the propagation and amplification of the blood coagulation cascade. It is composed of the activated serine protease Factor IXa and its essential non-enzymatic cofactor, Factor VIIIa, which assemble on the surface of activated platelets or other negatively charged phospholipid membranes in the presence of calcium ions (Source: StatPearls, Coagulation Cascade). The primary function of this complex is to catalyze the conversion of the zymogen Factor X into the active protease Factor Xa, a step that is critical for the subsequent large-scale generation of thrombin (Source: UniProt P00451). Deficiencies in the components of this complex lead to the X-linked bleeding disorders Hemophilia A (Factor VIII deficiency) and Hemophilia B (Factor IX deficiency), where the inability to form the tenase complex results in inadequate fibrin clot formation (Source: NIH, Hemophilia). Therapeutic targeting of this assembly includes replacement of the missing factors or the use of bispecific antibodies like emicizumab, which mimics the scaffolding function of Factor VIIIa to bridge Factor IXa and Factor X (Source: NEJM, Emicizumab). Additionally, the complex is a target for anticoagulant development, as its inhibition can prevent pathological thrombosis while potentially maintaining a safer bleeding profile compared to downstream thrombin inhibitors.

Other names

Factor IXa-VIIIa complexFIXa-FVIIIa complexIntrinsic tenaseTenase assemblyFactor IXa-Factor VIIIa assembly sites

The complex functions by positioning the protease Factor IXa and the substrate Factor X in close proximity on a phospholipid surface, with Factor VIIIa acting as a scaffold to dramatically increase the catalytic efficiency of Factor X activation (Source: Journal of Thrombosis and Haemostasis). Therapeutic mimics like emicizumab provide a structural scaffold to orient Factor IXa and Factor X in the absence of Factor VIIIa (Source: NEJM).